Target intelligence / Profile preview

Kinesin family member 20B (KIF20B)

Target
KIF20B
Molecular classification
Motor protein, Kinesin superfamily (kinesin-6 family), Enzyme (ATPase activity), Other (microtubule-associated protein)
01

Overview

Kinesin family member 20B (KIF20B), also known as MPHOSPH1 or M-phase phosphoprotein 1, is a plus-end-directed kinesin-6 family motor protein crucial for cytokinesis, the final step of cell division. It possesses ATPase activity, drives microtubule-dependent movement, and is phosphorylated during the G2/M cell cycle transition, facilitating proper cell division. KIF20B is overexpressed in various cancers and its upregulation is linked to tumorigenesis, advanced tumor stage, metastasis, and poor prognosis. Functional inhibition of KIF20B results in failed cytokinesis, mitotic arrest, and apoptosis, highlighting it as a promising therapeutic target in oncology. High KIF20B expression can also serve as a tumor biomarker. Its complex with partners like PRC1 is implicated in cancer cell survival and proliferation, especially in genitourinary and hepatocellular malignancies. No approved small molecules directly target KIF20B, but experimental gene silencing and combination approaches enhance antitumor efficacy in preclinical models.

Other names
MPHOSPH1M-phase phosphoprotein 1MPP1Kinesin-like protein KIF20BKinesin-related motor protein-interacting protein 1 (KRMP1)CT90
02

Mechanism of action

Inhibition leads to mitotic arrest, apoptosis, inhibition of cellular proliferation, and increased sensitivity to mitotic inhibitors (e.g., taxol)

03

Biological functions

Cell division (cytokinesis)Cell proliferationG2/M cell cycle transitionMicrotubule dynamics regulationSignal transduction (via STAT3 phosphorylation modulation)
04

Disease associations

CancerOncogenesis (notably in hepatocellular carcinoma, bladder cancer, colorectal cancer, breast cancer, pancreatic cancer, testicular germ cell tumors, and tongue cancer)
05

Safety considerations

Potential concerns include effects on normal proliferating tissues given the essential role in cytokinesis; risk of toxicity to dividing cells in healthy tissues is possible but not fully characterized
06

Interacting drugs

No clinically approved drugs; experimental interventions include siRNA, shRNA, and potential targeting with taxol combination in research models
07

Biomarkers

High KIF20B/MPHOSPH1 expression can serve as a prognostic biomarker for poor cancer outcomes and is associated with advanced disease stage and metastasis in several cancers

Beyond the preview

Go deeper on Kinesin family member 20B (KIF20B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kinesin family member 20B (KIF20B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call